At one time, Allergan was so confident it could lock up an acquisition of Salix Pharmaceuticals to thwart Valeant's hostile bid that it reportedly snubbed potential white knight Actavis when it came calling. But those talks have long since stalled, and now, Salix is investigating an inventory blip that The Wall Street Journal's sources say was a dealbreaker.
Building political tensions between Russia and the West are making it increasingly difficult for drugmakers in the region, prompting Germany's Fresenius to dump a partnership there. The announcement comes as other drug companies have reported their businesses are under pressure in the area.
Amid the pharma's slimdown craze, Belgium's UCB is getting in on the action by selling its U.S. generic drug unit for $1.53 billion.
Johnson & Johnson just scored a marketing goal: Its hepatitis C drug Olysio won FDA approval as part of a two-drug cocktail that also stars Gilead Sciences' Sovaldi. The question now is how much that approval will help Olysio withstand competition, both current and forthcoming.
A $1.64 billion breakup fee may have placated buyout target Shire after AbbVie pulled the plug on their $55 billion agreement. But investors? At least one may still be planning a little ax-grinding.
The BBC has some numbers sourced from GlobalData showing that 9 out of 10 Big Pharma companies do in fact spend more on marketing than on R&D. In some cases, that's twice as much.
AstraZeneca hiked its 2014 forecast for the second time this year. Sales were up by 5%. Instead of apologizing for a lack of growth, CEO Pascal Soriot could crow about the opposite. Revenue of $6.54 billion beat analyst estimates, and core EPS of $1.05 did the same.
Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market.
These days, the orphan drug business is a good place to win laurels. Which drugmakers are in line for the most impressive crowns?
Sanofi's U.S. diabetes sales team is under a worldwide spotlight--and not because it's time to take a bow.
Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it's always nice to know that would-be job seekers think your company is swell. Here's the latest gauge of drugmakers' status in the world of recruiting.
When it comes to cattle feed additive Zilmax, pulled from the market last year on concerning side-effect reports, there's nothing to worry about, Merck says. After a comprehensive review, the drugmaker has determined the product is safe when used according to its label. Now it just has to convince the meat-packing industry.
Actavis has been inking deals with Forest Laboratories and Warner Chilcott to get its hands on the companies' suite of branded products. Now, the company is celebrating the fruits of its labor with promising Q3 numbers and a slew of new deals on the horizon.
Valeant and partner Bill Ackman have dodged a serious roadblock in their quest to acquire Allergan. A 9.7% roadblock, if you will.
Olivier Bohuon, the CEO of artificial hip and knee maker Smith & Nephew may have a leg up over other potential candidates to take the reins of drugmaker Sanofi after the firing of Christopher Viehbacher last week. He has experience in pharma and has excelled at Smith & Nephew by moving it into new markets. Most importantly, he is French.
AstraZeneca signed on the dotted line for Almirall, gaining access to the company's promising respiratory drug portfolio and products currently under development. But now job cuts are on the horizon for Almirall, as the company is slashing jobs and sending some of its employees to AstraZeneca as part of the deal.
Here's something Regeneron isn't used to: Cutting sales forecasts for blockbuster eye drug Eylea. But that's just what the New York biotech did Tuesday amid lower-than-expected third-quarter results.
Actavis nabbed a big portfolio of branded products when it bought Forest Laboratories earlier this year. But it also inherited a quality-control problem.